Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial

Novo Nordisk’s late-stage weight loss data showed CagriSema performed below analysts’ expectations. It's the second late-stage clinical letdown for the candidate, and the findings mean it is more vital than ever that CagriSema succeeds in ...